Microcap bioresearch firm Adventrx Pharmaceuticals (ANX -1.1%) is lower today after the FDA says...

|By:, SA News Editor

Microcap bioresearch firm Adventrx Pharmaceuticals (ANX -1.1%) is lower today after the FDA says the company will need to repeat a study of its lung-cancer treatment Exelbine because it can't verify the authenticity of certain drugs in the previous trial. The shares have been pummeled this year, down nearly 78% since mid-July.